Clinical Trial Update: SAMBA EU Femoropopliteal Trial [NA]

View source ↗

Summary

An update on the SAMBA EU Femoropopliteal trial sponsored by NovoStent for Peripheral Vascular Disease. The current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Vascular Disease

Drugs mentioned

• SAMBA Stent

Snippet

Sponsor: NovoStent Corporation | Conditions: Peripheral Vascular Disease | NA | Status: UNKNOWN